TrialRheumatology (Oxford, England)2017

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.

Paul Emery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.